Vice President, Clinical Development
- Vice President, Clinical Development
Speakers: Scott Braunstein, M.D., Chief Executive Officer and Joe Hulihan, M.D., Chief Medical Officer
All of the above public webcasts may be accessed through the Events & Presentations page of the Investors & Media section of the Marinus website, www.marinuspharma.com .
- Marinus Pharmaceuticals, Inc. is a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders.
- Ganaxolone is a positive allosteric modulator of GABAA receptors that acts on a well-characterized target in the brain known to have anti-seizure, antidepressant and anti-anxiety effects.
- The company has initiated a Phase 3 trial in refractory status epilepticus.